Virpax Pharmaceuticals, Inc. (VRPX): Price and Financial Metrics


Virpax Pharmaceuticals, Inc. (VRPX): $0.81

0.00 (-0.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VRPX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VRPX Stock Price Chart Interactive Chart >

Price chart for VRPX

VRPX Price/Volume Stats

Current price $0.81 52-week high $2.50
Prev. close $0.81 52-week low $0.61
Day low $0.78 Volume 34,400
Day high $0.82 Avg. volume 30,178
50-day MA $0.78 Dividend yield N/A
200-day MA $1.25 Market Cap 9.44M

Virpax Pharmaceuticals, Inc. (VRPX) Company Bio


Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company. The Company focuses on pain management by developing and delivering non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology.


VRPX Latest News Stream


Event/Time News Detail
Loading, please wait...

VRPX Latest Social Stream


Loading social stream, please wait...

View Full VRPX Social Stream

Latest VRPX News From Around the Web

Below are the latest news stories about VIRPAX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VRPX as an investment opportunity.

Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, and central nervous system (CNS) disorders, today announced that it will utilize leading pain expert, Dr. Neil K. Singla, to assist in the design and support of the clinical development strategy for Probudur. Probudur is Virpax’s post-operative, ultra-long-acting anesthetic injecti

Business Wire | January 18, 2023

Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur

Virpax Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, and central nervous system (CNS) disorders, today announced that it will utilize leading pain expert, Dr. Neil K. Singla, to assist in the design and support of the clinical development strategy for Probudur.

Wallstreet:Online | January 18, 2023

Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts

BERWYN, Pa., January 10, 2023--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that the Company has engaged Destum Partners, Inc. to serve as the exclusive advisor for the Company's partnering and licensing efforts in strategic global markets. This initial engagement will en

Yahoo | January 10, 2023

Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has engaged two leading physicians experienced in childhood epilepsy, Dr. Kenneth W. Sommerville and Dr. Lawrence Fried, to support the overall development plan for NobrXiol. Their involve

Business Wire | January 4, 2023

Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol (formerly VRP324)

Virpax Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has engaged two leading physicians experienced in childhood epilepsy, Dr. Kenneth W. Sommerville and Dr. Lawrence

Wallstreet:Online | January 4, 2023

Read More 'VRPX' Stories Here

VRPX Price Returns

1-mo 21.80%
3-mo -21.36%
6-mo -46.00%
1-year -59.90%
3-year N/A
5-year N/A
YTD 30.16%
2022 -81.86%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5767 seconds.